Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy

By afschroeder • June 24, 2026

Othus M, Truong TG, Sharon E, Kendra K, Grossmann K, Buchbinder E, Khushalani NI, Eroglu Z, Chandra S, Doolittle GC, Kirkwood JM, Ikeguchi A, Mihalcioiu C, Cowey CL, Reddy SA, Johnson DB, Taylor M, Sondak VK, Ribas A, Patel SP. Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy. JCO Oncol Pract. 2026 Jun 23:OP2501413. doi: 10.1200/OP-25-01413. Epub ahead of print. PMID: 42335437.

Tags: Hematology/Oncology, Publications

Endometrial Serous Carcinoma Arising From Adenomyosis

Arzoo KK, Berkowitz MJ. Endometrial Serous Carcinoma Arising From Adenomyosis. Cureus. 2026 May 22;18(5):e109441. doi: 10.7759/cureus.109441. PMID: 42333330; PMCID: PMC13283456.

Mapping and engineering the human cell-cell interactome

Di Carlo D, Morsut L, McCain ML, Wright HJ, Abedi M, Yamada-Hunter SA, Zhang JZ, Backus K, Chung E, Wang Y, Rando TA, Cai L,[...]

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial

Olszewski AJ, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney MS, Woszczyk D, Giannopoulos K, Jurczak W, Jing J, Li[...]